A Study of CLSP 5282 in HLA-A*03:01 Positive Adult Patients With Solid Tumors (SENTINEL-101)

ClinicalTrials.gov ID

NCT07650357

Lead Sponsor

Clasp Therapeutics, Inc.INDUSTRY

Overall Status

Not yet recruiting

Study Type

Interventional

Phase

Phase 1

Enrollment

140Estimated

Last Update Posted

Jun 16, 2026Actual

Start Date

Jul 2026Estimated

Primary Completion Date

May 2029Estimated

Completion Date

Jul 2029Estimated

Official Title

SENTINEL-101: A Phase 1 Dose Escalation and Expansion Study of CLSP-5282 in HLA-A*03:01 Positive Adult Patients With Solid Tumors That Harbor the KRas G12V Mutation

Brief Summary

Phase 1, open-label, multicenter study to evaluate the safety, tolerability, PK, PD, and preliminary clinical activity of CLSP 5282 when administered to HLA A*03:01-positive adult patients with advanced solid tumors that harbor the KRas G12V mutation.

Detailed Description

CLSP-5282-101 is a Phase 1, open-label, multicenter study designed to evaluate the safety, tolerability, PK, PD, and preliminary clinical activity of CLSP-5282 when administered to HLA A*03:01-positive adult patients with advanced solid tumors that harbor the KRas G12V mutation.

The study will be conducted in 2 parts:

Part A Monotherapy Dose Escalation to determine the MTD and/or RDE(s) to characterize safety and clinical activity of CLSP-5282.

Part B Monotherapy Expansion to explore the preliminary antitumor activity and further characterize the safety, tolerability, PK, and PD of CLSP-5282 at the RDE(s). Part B will include three indication-specific cohorts in pancreatic adenocarcinoma (PDAC), colorectal cancer (CRC), and non-small cell lung carcinoma (NSCLC) as well as an all-other solid tumor cohort.

• Advanced Solid Tumor
• Non Small Cell Lung Cancer
• Pancreatic Carcinoma
• Colorectal Cancer

• CLSP-5282

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

• Adults at least 18 years of age on the day of signing informed consent.
• Willing and able to provide written informed consent for the study.
• Histologically or cytologically diagnosed, locally advanced or metastatic solid tumors that have progressed after standard of care therapy or for which no standard therapy exists.
• Tumors must harbor the KRas G12V mutation confirmed by the site's local or preferred tissue or ctDNA testing platform in an accredited laboratory.
• Patients must be HLA-A*03:01 positive by central assay.
• Eastern Cooperative Oncology Group performance status of 0 or 1.
• Adequate hematological, renal and hepatic function.
• Per Investigator judgement, patient is willing and able to complete study visits and/or procedures per the protocol and comply with study requirements for study participation.

Exclusion Criteria:

• Patients who have received other KRas G12V directed cellular therapies or TCEs.
• Patients may not be on other anticancer therapies at the time of the first dose of CLSP-5282. Exceptions upon agreement with Sponsor.
• Any other primary malignancy within the 2 years prior to first dose of study treatment except for non-melanoma skin cancer, carcinoma in situ (e.g., cervix, bladder, breast), or prostate cancer in remission.
• Patients who have not fully recovered from adverse events due to previous anticancer therapies
• Patients with active infection requiring systemic antimicrobial therapy
• Known primary malignant brain tumors, active central nervous system metastases and/or carcinomatous meningitis

Primary Purpose

Treatment

Allocation

Non-Randomized

Interventional Model

Sequential Assignment

Masking

None (Open Label)

Lead Sponsor

Clasp Therapeutics, Inc.INDUSTRY

972-566-3000

• A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

  NCT06778863

  RecruitingInterventionalPhase 1Updated Feb 13, 2026
• A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors

  NCT05117476

  Active, not recruitingInterventionalPhase 1Updated Nov 24, 2025
• A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation

  NCT06385925

  RecruitingInterventionalPhase 1Phase 2Updated Apr 24, 2026
• A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation

  NCT04165031

  TerminatedInterventionalPhase 1Phase 2Updated Nov 24, 2021
• Safety and PK Study of CC-90003 in Relapsed/Refractory Solid Tumors

  NCT02313012

  TerminatedInterventionalPhase 1Updated Nov 18, 2019
• A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer

  NCT04036682

  Active, not recruitingInterventionalPhase 1Phase 2Updated Jun 17, 2026